Action on Hearing Loss Logo
    Total results:
    Search
      Total results:
      Research Summit

      Programme

      A one-day summit that brings together opinion leaders and stakeholders from around the world to share and discuss the biggest challenges and opportunities in the development of treatments for hearing loss and tinnitus.

      9:00 Welcome

      Paul Breckell, CEO Action on Hearing Loss
      Prof. Jonathan Gale, Interim Director University College London (UCL) Ear Institute
      Dr. Ralph Holme, Director of Research at Action on Hearing Loss

      Session 1: Clinical trials - the learning curve

      (chaired by Prof. Anne Schilder, NIHR UCLH BRC Deafness and Hearing Problems theme)

      The Clinical and Patient Need

      Prof. Douglas Hartley, University of Nottingham & NUH NHS Trust

      Challenges and Opportunities of Early Phase Trials in Hearing Disorders and Tinnitus

      Prof. Anne Schilder, NIHR UCLH BRC Deafness and Hearing Problems theme  

      Questions & Answers with:

      Hugh Strickland, Corporate Finance Partner, who is partially deaf in both ears

      Morning refreshments and networking

      Preclinical and Clinical Development

      Dr. Richard Colvin, Executive Director Translation Medicine, Novartis

      Dr. Charles Large, Founder and CEO, Autifony Therapeutics

      Dr. Alan C. Foster, Vice President Research, Otonomy

      Dr. Penelope Brock, Fennec Pharmaceuticals

      Lunch and networking

      Session 2: Building on success - opportunities and challenges

      (chaired by Dr. Carina Santos,  Translational Research Manager at Action on Hearing Loss)

      Molecular Mechanisms and New Therapeutic Targets

      Prof Jonathan Gale, Interim Director UCL Ear Institute

      Showcase presentations (10 minutes each, no questions)

      A session for researchers to present their work with translational potential to industry and investors 

      1. Prof. Marcelo Rivolta, The University of Sheffield
      2. Prof. Gary Housley, The University of New South Wales
      3. Dr. Guillaume Duvey, CSO Pragma Therapeutics
      4. Prof. Benjamin Shapiro, CEO Otomagnetics
      5. Prof. Edwin Rubel, University of Washington 
      6. Dr. Roland Shaette, UCL Ear Institute
      7. Prof. Deborah Hall, University of Nottingham & NIHR Nottingham Biomedical Research Centre
      8. Shoba Dawson, evidENT

      Opportunities and Challenges in the Development of Therapies for Hearing Loss and Tinnitus. A Pharma Perspective

      Dr. Rick Cousins,  Research Director, GSK 

      Afternoon refreshments

      Panel Discussion 

      “How to accelerate the development of biological and pharmacological treatments for hearing loss and tinnitus?”

      (Chaired by Dr Sohaila Rastan, Action on Hearing Loss) 

      1. Rolf-Jan Rutten, CEO Audion Therapeutics
      2. Dr. August Wilke, Eli Lilly and Company
      3. Dr. Erik Larsen, Senior Director of Hearing Science and Technology, Decibel Therapeutics
      4. Prof. Karen Steel, King’s College London
      5. Prof. Gary Housley, The University of New South Wales
      6. Prof. Deborah Hall, University of Nottingham & NIHR Nottingham Biomedical Research Centre 
      7. Dr. Ralph Holme, Action on Hearing Loss

      17:30 Drinks reception and networking

       

       

       

      Register now

      The event will be popular, so register as soon as possible to guarantee your place.

      Registration closes on 19 February 2018.

      If you have any questions about the summit, please contact our Biomedical Research team.